

Managed Growth Fund

Fund Focus - June 2022



Investment Strategy

The Fund invests in a mix of Australian and international shares, fixed interest securities, listed property securities and cash. The Fund is designed to reduce investment risk by diversifying across asset classes.

Portfolio Characteristics

Funds Under Management	\$63.97m
Latest Distribution Date	30 June 2022
Latest Distribution Amount	0.1079
Benchmark	CPI+2.5% pa over rolling five year periods before fees and taxes.

Fund Facts

APIR Code	ZUR0059AU
Inception Date	2 April 1997
Total Est. Management Cost %	0.96
Est. Transactional Op. Cost %	0
Buy/Sell Spread %	0.12
Distribution Frequency	Quarterly

Fund Performance After Fees

	1 Month	3 Months	1 Year	3 Years	5 Years	Since Inception
Distribution	8.70	8.47	10.55	8.73	10.80	6.74
Growth	-13.45	-15.73	-17.78	-6.06	-5.82	0.29
Total	-4.75	-7.25	-7.23	2.68	4.97	7.03
Benchmark	-4.37	-6.82	-5.24	3.92	6.10	7.15

Strategic Investment Partners

Australian Shares

Antares Capital Partners
Celeste Funds Management Pty Limited
DWS International
Schroder Investment Management Australia
Tyndall Asset Management

International Shares

American Century Investment Management, Inc
Epoch Investment Partners, Inc
Lazard Asset Management Pacific Co
Realindex Investments Pty Limited
Allspring Global Investors

Australian Property Securities

Renaissance Property Securities Pty Ltd

Global Property Securities

Presima Inc

Fixed Interest and Cash

Schroder Investment Management Australia

Infrastructure

Lazard Asset Management Pacific Co

Alternative Investments

Insight Investment Management (Global)
Robeco Hong Kong Ltd

Absolute Return Bond

AllianceBernstein Investment Management


Risk Statistics

1 Jul 2017 to 30 Jun 2022


Std Dev	9.01
Sharpe Ratio (arith)	0.55

Investment Growth (\$10,000)

1 Jul 2017 to 30 Jun 2022



Portfolio Equity Sectors (%)



● Absolute Return Bonds	7.00
● Alternatives	8.95
● Australian Property	1.88
● Australian Shares	28.91
● Diversified Fixed Interest	14.66
● Global Property	1.76
● Infrastructure	2.24
● International Shares	28.12
● Liquidity	6.49

Actual Asset Allocation

	Actual Asset Allocation %	Benchmark Weight %	Active Position %
Absolute Return Bonds	7.0	8.0	-1.0
Alternatives	9.0	9.0	0.0
Australian Property	1.9	2.0	-0.1
Australian Shares	28.9	29.0	-0.1
Diversified Fixed Interest	14.7	16.0	-1.3
Global Property	1.8	2.0	-0.2
Infrastructure	2.2	2.0	0.2
International Shares	28.1	28.0	0.1
Liquidity	6.5	4.0	2.5

Market Commentary

The Zurich Investments Managed Growth Fund fell by 7.25% in the June quarter.

World equity markets tumbled in the second quarter as investors grew increasingly nervous about the global economic outlook. The period was a volatile one, marked by the steady drumbeat of negative news about inflation and the response of monetary policymakers worldwide to contain this threat. Markets swerved between gains and losses, as investors grappled with two competing sentiments—relief that central banks were taking aggressive actions to rein in soaring prices, and anxiety that these same actions could tip the global economy into a recession. The quarter did provide some potentially positive developments on the inflation front, thanks to news coming out of China, where the Chinese government continued to loosen restrictions on major cities struggling to contain a rapidly spreading coronavirus outbreak, including those cities that serve as global manufacturing hubs. Investors were hopeful that this action will ease supply chain bottlenecks and alleviate inflationary pressure, as well as spur China's sputtering economy and re-open the country's vast consumer markets to major trading partners such as the European Union and Japan.

The MSCI World Health Care Index posted a slight gain in Australian currency, while the broad market MSCI World Index was sharply lower. Many of the health care stocks are attractive for their more resilient earnings during economic downturns. That's why pharmaceutical companies and health care providers held up well. Pharmaceuticals stocks gained outright, as relative valuations and comparatively strong cash flows made them attractive in a volatile environment. Certain growth-oriented industries, such as biotechnology, became increasingly attractively valued after past underperformance. As a result, biotech stocks also held up well and generated positive returns in Australian dollars.

The S&P/ASX Small Ordinaries Accumulation Index decreased by 20.4% in the June quarter as central banks aggressively raised rates, fanning concerns about a potential synchronised global recession. As a result, commodity prices rolled over, and markets sold off heavily. The significant outperformance of the resource names began to unwind in the quarter due to weakness in commodities and investor sentiment. At quarter-end, outperformance came from higher quality industrials with limited resources exposure.

The AREIT market fell heavily in the June quarter as markets were driven by accelerating fears around rising inflation, aggressive central bank tightening, surging bond yields and growing fears around a global recession. The main AREIT news for the quarter included several stocks reporting quarterly results, M&A activity and six-monthly revaluations.

* Performance returns quoted are compound rates of return calculated on exit prices and assume reinvestment of distributions. Returns are calculated net of all ongoing fees and any taxes payable by the fund. Total return includes both growth and distribution returns. Growth return is the change in exit price over the relevant period. The benchmark return shown is a gross return. Please note that figures shown are rounded to one decimal place, therefore some rounding errors may occur.

^ The Estimated Total Management Cost of 0.96% includes an Estimated Performance Fee of 0% and Estimated Indirect Costs of 0.09%.

Past performance is not a reliable indicator of future performance.

This report is issued by Zurich Investment Management Limited ABN: 56 063 278 400, AFSL: 232511, GIIN: FVHHKJ.00012.ME.036 : . The information in the report has been derived from sources reasonably believed to be reliable and accurate and is to be used for research purposes only. Subject to law, none of the companies of the Zurich Financial Services Australia Limited Group, nor their directors or employees, gives any representation or warranty as to the reliability, accuracy or completeness of the information, nor accepts any responsibility arising in any way (including by reason of negligence) from errors in or omissions from, the information provided. A Product Disclosure Statement (PDS) for the Fund is available and can be obtained by calling Zurich Investments on 131 551. The PDS should be considered in deciding whether to acquire, or to continue to hold, an investment in the fund. This information is of a general nature only and does not take into account the investment objectives, financial situation or particular needs of any investor and should not be taken as a securities or stock recommendation. These factors should be considered before any investment decision is made in relation to the fund. Furthermore, this product has been designed to meet certain objectives, financial situations and needs, which are described in our Target Market Determination available at zurich.com.au/tmd

PIRD-018926-2022